Hee Soo Kim1, Se Lee Kwon1, Seung Hong Choi2,3,4, Inpyeong Hwang5,6, Tae Min Kim7, Chul-Kee Park8, Sung-Hye Park9, Jae-Kyung Won9, Il Han Kim10, Soon Tae Lee11. 1. College of Medicine, Seoul National University, Seoul, South Korea. 2. Department of Radiology, College of Medicine, Seoul National University, 28, Yongon-dong, Chongno-gu, Seoul, 110-744, South Korea. verocay@snuh.org. 3. Center for Nanoparticle Research, Institute for Basic Science, Seoul, South Korea. verocay@snuh.org. 4. School of Chemical and Biological Engineering, Seoul National University, Seoul, 151-742, South Korea. verocay@snuh.org. 5. Department of Radiology, College of Medicine, Seoul National University, 28, Yongon-dong, Chongno-gu, Seoul, 110-744, South Korea. 6. Center for Nanoparticle Research, Institute for Basic Science, Seoul, South Korea. 7. Department of Internal Medicine, Cancer Research Institute, College of Medicine, Seoul National University, Seoul, South Korea. 8. Department of Neurosurgery, Biomedical Research Institute, College of Medicine, Seoul National University, Seoul, South Korea. 9. Department of Pathology, College of Medicine, Seoul National University, Seoul, South Korea. 10. Department of Radiation Oncology, Cancer Research Institute, College of Medicine, Seoul National University, Seoul, South Korea. 11. Department of Neurology, College of Medicine, Seoul National University, Seoul, South Korea.
Abstract
PURPOSE: To examine the applicability of contrast leakage information from dynamic susceptibility contrast-enhanced (DSC) MRI and dynamic contrast-enhanced (DCE) MRI to determine which one is the most valuable surrogate imaging biomarker for predicting disease progression in anaplastic astrocytoma (AA) patients. MATERIALS AND METHODS: This study was approved by the institutional review board (IRB), which waived informed consent. A total of seventy-three AA patients who had undergone preoperative DCE and DSC MRI and received standard treatment, including partial resection or biopsy followed by radiation therapy, were included in this retrospective study. Based on Response Assessment in Neuro-Oncology (RANO), patients were sorted into progression (n = 21) and non-progression (n = 52) groups. Tumor boundaries were defined as high-signal intensity (SI) lesions on fluid-attenuated inversion recovery (FLAIR) imaging, where we analyzed mean pharmacokinetic parameters (Ktrans, Vp, and Ve) from DCE MRI and contrast leakage information (mean extraction fraction (EF)) from DSC MRI. RESULTS: Mean Ve and mean EF were significantly higher in patients with progression-free survival (PFS) < 18 months than in those with PFS ≥ 18 months. For distinguishing the group with PFS < 18 months, AUC values were calculated using the mean Ve value (AUC = 0.716). The Kaplan-Meier survival analysis revealed that mean Ve value was significantly correlated with PFS. In Cox proportional-hazards regression, only the mean Ve value was found to be significantly associated with PFS. CONCLUSION: We found that the mean Ve value based on high-SI tumor lesions on FLAIR imaging was capable of predicting outcomes of AA patients as a potential surrogate imaging biomarker. KEY POINTS: • Mean Ve(2.152 ± 1.857 vs. 1.173 ± 1.408) was significantly higher in anaplastic astrocytoma patients with PFS < 18 months that in those with PFS ≥ 18 months (p = 0.02). • Cox proportional-hazards regression showed that only mean Ve(p = 0.034) was significantly associated with PFS, regardless of IDH mutation status, in anaplastic astrocytoma patients.
PURPOSE: To examine the applicability of contrast leakage information from dynamic susceptibility contrast-enhanced (DSC) MRI and dynamic contrast-enhanced (DCE) MRI to determine which one is the most valuable surrogate imaging biomarker for predicting disease progression in anaplastic astrocytoma (AA) patients. MATERIALS AND METHODS: This study was approved by the institutional review board (IRB), which waived informed consent. A total of seventy-three AApatients who had undergone preoperative DCE and DSC MRI and received standard treatment, including partial resection or biopsy followed by radiation therapy, were included in this retrospective study. Based on Response Assessment in Neuro-Oncology (RANO), patients were sorted into progression (n = 21) and non-progression (n = 52) groups. Tumor boundaries were defined as high-signal intensity (SI) lesions on fluid-attenuated inversion recovery (FLAIR) imaging, where we analyzed mean pharmacokinetic parameters (Ktrans, Vp, and Ve) from DCE MRI and contrast leakage information (mean extraction fraction (EF)) from DSC MRI. RESULTS: Mean Ve and mean EF were significantly higher in patients with progression-free survival (PFS) < 18 months than in those with PFS ≥ 18 months. For distinguishing the group with PFS < 18 months, AUC values were calculated using the mean Ve value (AUC = 0.716). The Kaplan-Meier survival analysis revealed that mean Ve value was significantly correlated with PFS. In Cox proportional-hazards regression, only the mean Ve value was found to be significantly associated with PFS. CONCLUSION: We found that the mean Ve value based on high-SI tumor lesions on FLAIR imaging was capable of predicting outcomes of AApatients as a potential surrogate imaging biomarker. KEY POINTS: • Mean Ve(2.152 ± 1.857 vs. 1.173 ± 1.408) was significantly higher in anaplastic astrocytomapatients with PFS < 18 months that in those with PFS ≥ 18 months (p = 0.02). • Cox proportional-hazards regression showed that only mean Ve(p = 0.034) was significantly associated with PFS, regardless of IDH mutation status, in anaplastic astrocytomapatients.
Entities:
Keywords:
Anaplastic astrocytoma; Magnetic resonance imaging; Perfusion; Permeability; Prognosis
Authors: Edward R Laws; Ian F Parney; Wei Huang; Fred Anderson; Angel M Morris; Anthony Asher; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew Sloan; Mitchel S Berger; Susan Chang Journal: J Neurosurg Date: 2003-09 Impact factor: 5.115
Authors: Anna K Heye; Ross D Culling; Maria Del C Valdés Hernández; Michael J Thrippleton; Joanna M Wardlaw Journal: Neuroimage Clin Date: 2014-09-10 Impact factor: 4.881
Authors: Inpyeong Hwang; Seung Hong Choi; Jin Wook Kim; Eung Koo Yeon; Ji Ye Lee; Roh-Eul Yoo; Koung Mi Kang; Tae Jin Yun; Ji-Hoon Kim; Chul-Ho Sohn Journal: Eur Radiol Date: 2022-01-27 Impact factor: 5.315
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639